Ultragenyx Pharmaceutical (RARE) shares dropped 26% after a phase 3 study update of UX143 missed a key efficacy metric in pediatric and young adult patients with osteogenesis imperfecta, a rare genetic bone disorder.
"Investors were disappointed" that the annualized fracture rate efficacy hurdle wasn't met, Wedbush Securities said Thursday in a report. UX143 is being developed in collaboration with Mereo BioPharma (MREO).
More than 10 million shares of Ultragenyx traded intraday compared with a daily average of about 1.07 million. Mereo sank 41% following an increase in intraday trading volume to over 25 million from a daily average of about 1.41 million.
Methode Electronics (MEI) late Wednesday reported a wider adjusted net loss and declining net sales in fiscal Q4.
Shares slumped 25% as intraday trading volume surged to more than 1.2 million from a daily average of roughly 291,000.
Helen of Troy (HELE) shares sank Thursday after the consumer products firm issued a downbeat Q2 outlook amid uncertainty around tariffs, which dented Q1 revenue by more than expected.
Shares slid 22%, with intraday trading volume at over 3.72 million, versus the stock's daily average of about 741,000.
Price: 30.50, Change: -10.94, Percent Change: -26.40
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.